GSK plc
GSK
$46.63
-$0.47-1.00%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.90% | 3.42% | 4.13% | 6.26% | 9.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.90% | 3.42% | 4.13% | 6.26% | 9.08% |
| Cost of Revenue | 5.65% | 7.54% | 7.02% | 8.28% | 2.50% |
| Gross Profit | 6.00% | 1.89% | 3.04% | 5.48% | 11.82% |
| SG&A Expenses | 3.67% | 0.78% | 0.67% | -0.06% | 2.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 37.34% | 59.45% | 72.83% | 75.24% | 26.93% |
| Total Operating Expenses | 7.23% | 7.96% | 8.65% | 9.93% | 6.51% |
| Operating Income | 2.40% | -7.82% | -7.28% | -3.34% | 16.49% |
| Income Before Tax | 121.45% | -5.72% | -23.02% | -41.54% | -53.70% |
| Income Tax Expenses | 120.98% | -7.52% | -22.05% | -29.09% | -41.58% |
| Earnings from Continuing Operations | 121.52% | -5.42% | -23.18% | -43.32% | -55.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -73.68% | -103.71% | -81.09% | -2.16% | 23.08% |
| Net Income | 128.01% | -13.09% | -29.53% | -46.81% | -57.52% |
| EBIT | 2.40% | -7.82% | -7.28% | -3.34% | 16.49% |
| EBITDA | 10.73% | 7.85% | 5.15% | 5.54% | 16.51% |
| EPS Basic | 128.62% | -13.33% | -29.99% | -47.12% | -57.78% |
| Normalized Basic EPS | -1.45% | -13.58% | -11.98% | -3.11% | 24.07% |
| EPS Diluted | 128.01% | -13.29% | -29.89% | -47.11% | -57.72% |
| Normalized Diluted EPS | -1.58% | -13.65% | -12.02% | -3.11% | 24.01% |
| Average Basic Shares Outstanding | -0.11% | 0.33% | 0.59% | 0.62% | 0.61% |
| Average Diluted Shares Outstanding | 0.01% | 0.43% | 0.68% | 0.70% | 0.68% |
| Dividend Per Share | 8.08% | 7.93% | 6.66% | 8.08% | 13.06% |
| Payout Ratio | -0.52% | 0.25% | 0.59% | 1.10% | 1.51% |